Five of the twelve Presidential Symposium late-breakers in Madrid trace back to molecules discovered in China. Here is what ...

RESTORE-3 study demonstrates a 60.4% proptosis response rate versus 23.5% with placebo at Week 24, highlighting the potential ...

Helfie AI ("Helfie"), an AI-powered preventive network transforming global healthcare, announced it has signed a Memorandum ...

The initiative combines NVIDIA’s accelerated computing ecosystem with GenScript’s laboratory validation expertise, offering ...

Clearance strengthens RingConn’s position in the US wearable health technology market, supporting its expansion in SpO2 ...

(9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study ...

Headline value is the wrong way to rank a year. We scored the contenders on four published criteria, split every headline into the money committed and the money that is merely possible, and the order ...

CellFiber, a biotechnology company specialising in cell and gene therapy technologies, has announced the official launch of ...

Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., ...

Novel RNAi therapeutic targeting INHBE aims to address obesity and associated cardiometabolic disorders Suzhou Ribo Life ...

OB-001 is a highly selective and effective inhibitor of two key efflux pumps (P-gp and BCRP), which are present both on the ...

Company plans to initiate clinical development of tonabersat in 2027, exploring a potential non-invasive treatment option for ...